



بسم الله الرحمن الرحيم

**Sudan University for Sciences & Technology**

**College of Graduate Studies**

**College of medical laboratory science**

**Clinical chemistry**



**Effect of Chemotherapy in Renal Function Test and Electrolyte in  
Cancer Patients in Khartoum State**

تأثير العلاج الكيميائي في اختبار وظائف الكلى والشوارد الكهربائية في مرضى  
السرطان في ولاية الخرطوم

**A Dissertation Submitted in Partial Fulfillment of the Requirement for  
M.Sc Degree in Medical Laboratory Sciences**

Prepared by:

**Nada Mustafa Ali Ahmed**

Bachelor of Medical Laboratory Sciences (2016)

Sudan University

**Supervisor:**

Prof: **Abdalkareem Abobaker**

PhD in clinical chemistry

**April 2021**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

## الآية

مَا أَبْرَأُ نَفْسِي إِنَّ النَّفْسَ لَأَمَّارَةٌ بِالسُّوءِ إِلَّا مَا رَحِمَ رَبِّي إِنَّ رَبِّي غَفُورٌ رَحِيمٌ (53) وَقَالَ الْمَلِكُ انْتُوْبِي  
بِهِ اسْتَخْلِصْهُ لِنَفْسِي فَلَمَّا كَلَّمَهُ قَالَ إِنَّكَ الْيَوْمَ لَدَيْنَا مَكِينٌ أَمِينٌ (54) قَالَ اجْعَلْنِي عَلَى خَزَائِنِ الْأَرْضِ  
إِنِّي حَفِيظٌ عَلِيمٌ (55) وَكَذَلِكَ مَكَّنَّا لِيُوسُفَ فِي الْأَرْضِ يَتَّبِعُونَ مِنْهَا حَيْثُ يَشَاءُ نُصِيبُ بِرَحْمَتِنَا مَنْ نَشَاءُ  
وَلَا نُضِيعُ أَجْرَ الْمُحْسِنِينَ (56)

سورة يوسف الآيات: (53-56)

## **DEDICATION**

**I dedicate this thesis to**

**My father**

**My mother**

**My husband**

**My son**

**My brothers**

**My teachers**

**And to all of my friends**

## **ACKNOWLEDGEMENT**

All thanks and praise to ALLAH the lord of all worlds for all givens rewards to me. With sincere thanks and gratefulness, I would like to acknowledge my Supervisor **Dr/ Abdalkreem Awad** for this outstanding, knowledge encouragement, guidance, patience and constructive advice throughout this work.

## *Abstract*

**Background:** conducted this study to evaluate the type and frequency of affected electrolytes. Electrolyte derangement has been documented during cancer chemotherapy leading to the electrolyte imbalance. and disturbance of renal function.

**Objective:** to assess frequency of electrolyte and renal function imbalance among cancer patient during chemotherapy

**Materials and Methods :**This was a cross sectional study concluded samples were collected using non-probability convenient sampling technique, the study conducted in PORJ AL AMAL hospital to determine the level of sodium , potassium, urea and creatinine .Blood samples were collected for the assessment of the sodium , potassium ,urea and creatine levels with the help of analyzer. A total of 70cancer patients were selected. the range of the included patient was 10 \_ 77 years who received single or combination chemotherapy. Data analysis was done using SPSS version 19 . one sample T test use to assess the significant after the treatment with P .value <0.5 and correlation test was done.

**Result:** the mean age of patients was 38. In our study significant difference existed in electrolytes parameters. In our study potassium level after the chemotherapy was 3.43 mg/dl (p<0.001) while sodium level after the

chemotherapy was 131.77mg/dl ( $p < 0.001$ ) . urea level after chemotherapy was 35.30mg/dl ( $p < 0.001$ ) . while recorded creatinine levels after chemotherapy was 0.82 mg/dl ( $p < 0.001$ ). Sodium, potassium, creatinine and urea levels show significant p value.

**Conclusion:** Our study demonstrates that electrolyte imbalances are common during chemotherapy and monitoring should be done .

## المستخلص

خلفية: تم توثيق اختلال الشوارد الكهربائية أثناء العلاج الكيميائي للسرطان مما أدى إلى اختلال توازن الشوارد الكهربائي. لذلك نحن اجرينا هذه الدراسة لتقييم نوع وتكرار الشوارد الكهربائية.

الادوات والطرق: كانت هذه دراسة مقطعية وتم جمع العينات باستخدام تقنية اخذ العينات الاحتمالية الملائمة غير المصابة ، اجريت في مستشفى برج الامل لتحديد مستوى الصوديوم والبوتاسيوم واليوريا والكرياتنين.

وتم جمع عينات الدم لتقييم مستويات الصوديوم والبوتاسيوم واليوريا والكرياتنين بمساعدة محلل. تم تضمين مجموعة 70 مريضا بالسرطان ، وتشمل معايير الاشتغال النطاق العمري 10-77 سنة الذين تلقوا العلاج الكيميائي الفردي او المركب .

تم اجراء تحليل البيانات باستخدام الحزمة الاحصائية للعلوم الاجتماعيه الاصدار 19 كان متوسط عمر المرضى 38.

النتائج: في دراستنا كان هناك فرق كبير في مستوى الشوارد الكهربائية. في دراستنا كان مستوى البوتاسيوم بعد العلاج الكيميائي 3.43 مجم/ديسيلتر (القيمة الاحتمالية اصغر من 0.001) بينما كان مستوى الصوديوم بعد العلاج الكيميائي 131.77 مجم /ديسيلتر (القيمة الاحتمالية اصغر من 0.001) كان مستوى اليوريا بعد العلاج الكيميائي 35.3 مجم /ديسيلتر (القيمة الاحتمالية اصغر من 0.001) بينما سجلت مستويات الكرياتنين بعد العلاج الكيميائي كان 0.82 مجم/ديسيلتر (القيمة الاحتمالية اصغر من 0.001) تظهر مستويات الصوديوم والبوتاسيوم والكرياتنين واليوريا بشكل كبير نتيجة للقيمة الاحتمالية.

الخاتمة: توضح دراستنا ان الاختلالات في الشوارد الكهربائيه شائعة أثناء العلاج الكيميائي ويجب المراقبة.

Subject	i
الآية	ii
Dedication	iii
Acknowledgment	iv-v
Abstract	vi
المستخلص	vii-ix
List of content	x
List of figures	xi
List of abbreviation	xii
Chapter One	
Introduction – Rational – Objective	
1.1 Introduction	1
1.2 Rational	2
1.3 Objective	2
1.3.1 General objective	2
1.3.2 Specific objective	2
Chapter two	
Literature Review	
2.1 Renal physiology	4
2.1.2 Function of the kidney	4
2.2 Electrolyte	4
2.2.1 Potassium	4
2.2.1.1 Distribution of potassium (K) in the body	5
2.2.1.2 Hypokalemia	5
2.2.1.3 Hyperkalemia	6
2.2.2 Sodium	7
2.2.2.1 Hyponatremia	7
2.2.2.2 Hypernatremia	7
2.2.3 Urea	8
2.2.3.1 Urea Cycle Disorder (UCD)	8
2.2.4 Creatine	8
2.2.5 Creatinine	8
2.2.5.1	8
2.6 Chemotherapy	9
2.6.1 Chemotherapy Definition	9
2.6.2 Common chemotherapeutic agent	9
Chapter Three	
Materials and Methods	
3.1 Materials	10



3.1.1 Study design	10
3.1.2 Study area	10
3.1.3 Study period	10
3.1.4 Target population and sample size	10
3.1.5 Inclusion criteria	10
3.1.6 Exclusion criteria	10
3.1.7 Ethical consideration	10
3.1.8 Data collection and analysis	10
3.1.8.1 Blood samples collection	11
3.2 Methods	
3.2.1 Measurement of potassium	11
3.2.1.1 Principle	11
3.2.1.2 Procedure	11
3.2.2 Measurement of sodium	11
3.2.2.1 Principle	11
3.2.2.2 Procedure	12
3.2.3 Measurement of urea	12
3.2.3.1 Principle	12
3.2.3.2 Procedure	12
3.2.4 Measurement of Creatinine	12
3.2.4.1 principle	12
3.2.4.2 Procedure	12
3.3 Quality control	13
3.4 Statistical analysis	13
Chapter four	
Results	
4. Results	14
Chapter five	
Discussion – Conclusion – Recommendations	
5.1 Discussion	16
5.2 Conclusions	16
5.3 Recommendations	16
References	18
<b>Appendices</b>	

Appendices
Appendix 1
Appendix 2
Appendix 3
Appendix 4

List of figures

Figure (4.1) Correlation between Urea level and Age	
Figure (4.2) Correlation between Creatinine and Age	
Figure (4.3) Correlation between Sodium and Age	
Figure (4.4) Correlation between Potassium and Age	

# Chapter one

## 1.1introduction

Cancer patients are usually encountered by number of different issues one of them include electrolyte imbalance (Bowman BT.,2017).

Other causes of electrolyte imbalance include para neoplastic syndrome or those associated with chemotherapeutic regimes (Nriagu J et al., 2016 ). Life threatening complication has been documented because of these malignant specific electrolyte disorders they may require urgent therapy and correction. Therefore on time proper recognition and urgent treatment of such patients are overall important (Kumar RV and Bhasker .,2015). Among the electrolyte disorder in malignant patient's hyponatremia is the most common. In one of the study 14% of patients presented were cancer related (Allolio B et al.,2014). About half of hyponatremia patients are hospital acquired cases suggesting that proper care and management plan can help to prevent development of hyponatremia (Moritz ML and Ayus JC.,2014 ) Changes in potassium level in cancer patients especially hyperkalemia is attributable to rhabdomyolysis (Lameire N et al ., 2010) , renal injury or tumor lysis syndrome Potassium imbalance especially hypokalemia is the second most common electrolyte imbalance documented in cancer patients( Carvalho F et al., 2015) These potassium related imbalance can be because of other causes, some medications like as ifosfamide, cisplatin, amphotericin B, and amino glycoside antibiotics are responsible for tubular damage leading to kidney and get losses of potassium leading to hypokalemia.

## 1.2 Rationale

Cancer cell treated with different type of therapy one of the therapy method is chemotherapy and it is effect cell and cause damage. Measuring of renal profile and electrolyte help in monitoring the patient and its treatment during chemotherapy .if there any abnormal mean that chemotherapy effect on renal function.

### **1.3objective**

#### **1.3.1General objective**

Assessment of renal function in cancer patients under chemotherapy.

#### **1.3.2 specific objectives**

To measure urea and creatinine .

To measure sodium and potassium.

To correlate between age and renal function abnormalities

## **Chapter Two**

### **2 . Literature review**

#### **2.1renal physiology**

Renal system consist of : Kidneys ,blood supply(renal arteries and veins)  
Ureter ,urinary bladder ,urethra. (Bowman BT.2017).

### 2.1.2 function of kidney

Water balance

,Electrolyte balance

Plasma volume

Acid-base balance

Excretion Hormone secretion(Bishop *et al* ., 2010).

### 2.2Electrolyte

Electrolytes are anions or cations depending on whether they move in an electrical field toward the anode or the cathode that is whether they have a positive or negative charge. The major electrolytes included are sodium (Na), potassium (K) , calcium (Ca), magnesium (Mg), chloride (Cl), bicarbonate (HCO<sub>3</sub>), phosphate (HPO<sub>4</sub>), sulphate (SO<sub>4</sub>) , and lactate as well as few other organic anions and trace elements(Bishop *et al* ., 2010) .

#### 2.2.1potassium

Potassium is an essential mineral and a major electrolyte found in the human body. It plays an important role in electrolyte regulation, nerve function, muscle control, and blood pressure. Potassium is found within all cells of the body, and its levels are controlled by the kidneys. Primarily, potassium functions to regulate water and mineral balance throughout the body Potassium works with sodium to maintain the body's normal blood pressure. Research suggests that increasing dietary potassium may provide a protective effect against hypertension (high blood pressure) by increasing

the amount of sodium excreted from the body. A high potassium intake has also been linked to a reduced risk of death due to cardiovascular disease.(Colorada state university2013 ).

#### 2.2.1.1 Distribution of potassium (K) in the body

Most of potassium is located in body cells. Note entry of potassium into the small intestine, where it is extensively reabsorbed. Potassium may be secreted in the colon.

Potassium exit from the body is mediated both by the kidney and to a lesser extent ,by the colon.

The distribution of potassium between extra- and intracellular fluid is dependent and regulated by a pump-leak mechanism involving both Na-K-ATP ase and membrane K channels.(G Giebisch *et .*, 2007).

#### 2.2.1.2 Hypokalemia

Hypokalemia (serum potassium level less than 3.6 mEq per L [3.6 mmol per L]) occurs in up to 21% of hospitalized patients and 2% to 3% of outpatients. ( ANTHONYJ *et al.*,2015).

#### 2.2.1.3Hyperkalemia

Hyperkalemia is caused by excess potassium intake, impaired potassium excretion, or transcellular shifts. The etiology of hyperkalemia is often multi factorial, with impaired renal function, medication use, and hyperglycemia as the most common contributors.



Hyperkalemia (serum potassium level more than 5 mEq per L [5 mmol per L] in adults, more than 5.5 mEq per L [5.5 mmol per L] in children, and more than 6 mEq per L [6 mmol per L] in neonates) occurs in up to 10% of hospitalized patients and approximately 1% of outpatients. ( Anthonyj *et al.*,2015).

Because healthy individuals can adapt to excess potassium consumption by increasing excretion, increased potassium intake is rarely the sole cause of hyperkalemia, and underlying renal dysfunction is common (Evans KJ , Greenberg A.2005).

### 2.2.2sodium

Under normal conditions, plasma sodium concentrations are finely maintained within the narrow range of (135-145) m mol/l despite great variations in water and salt intake. Sodium and its accompanying anions, principally chloride and bicarbonate, account for 86% of the extracellular fluid osmolality, which is normally 285-295 mosm/kg and calculated as  $(2 \times [\text{Na}]\text{mmol/l} + [\text{urea}]\text{mmol.l} + [\text{glucose}]\text{mmol/l})$ . The main determinant of the plasma sodium concentration is the plasma water content, itself determined by water intake (thirst or habit), “insensible” losses (such as metabolic water, sweat), and urinary dilution. The last of these is under most circumstances the most important and is predominantly determined by arginine vasopressin, which is synthesized in the hypothalamus and then stored in and released from the posterior pituitary. In response to arginine vasopressin, concentrated urine is produced by water re absorption across the renal collecting ducts. This is mediated by specialized cellular membrane transport proteins called a quaporins.(Klein L *et al .*, 2005)

### 2.2.2.1 Hyponatremia

Hyponatremia (low blood sodium) is a condition that means you don't have enough sodium in your blood. You need some sodium in your bloodstream to control how much water is in and around the cells in your body. It can happen because of certain medical conditions, some medicines you might be taking, or if you drink too much water. Because of the low sodium, the amount of water in your body rises and causes your cells to swell. This can lead to many problems. Some are mild, but others can be serious and even life-threatening. How low is too low? Your blood sodium level is normal if it's 135 to 145 milli equivalents per liter (mEq/L). If it's below 135 mEq/L, it's hyponatremia. Your doctor will be able to tell you whether your level is too low. (Anderson R J. 1986).

### 2.2.2.2 Hypernatremia

Hypernatremia is a common electrolyte problem that is defined as a rise in serum sodium concentration to a value exceeding 145 mmol/L. [1, 2, 3] It is strictly defined as a hyperosmolar condition caused by a decrease in total body water (TBW) , relative to electrolyte content. Hypernatremia is a "water problem," not a problem of sodium homeostasis. (Anderson R J. 1986) .

### 2.2.3 Urea

Urea is the chief nitrogenous end product of the metabolic breakdown of proteins in all mammals and some fishes. These amino groups are converted to ammonia (NH<sub>3</sub>), which is toxic to the body and thus must be converted to urea by the liver. The urea then passes to the kidneys and is eventually excreted in the urine( Higgins C ,.2016).

#### 2.2.3.1 A urea cycle disorder(UCD)

A urea cycle disorder (UCD) is an inherited disease that affects how the body removes the waste that is made from breaking down protein. Everyone needs protein, which is found in foods like dairy products, meat and fish. When a person eats food that contains protein, the body breaks it down into amino acids (the building blocks of protein that are used by the body for growth and tissue repair) and uses only what it needs. It changes the rest into nitrogen, which must then be removed by the body( Higgins C ,.2016) .

#### 2.2.4 Creatinine

Creatinine is a biological waste product formed by the degradation of creatine in the muscle cell . it transported into the kidney through the blood and eliminated from the body in urine ,the amount of creatinine in the blood is proportional to the muscle mass in the body in healthy person . blood creatinine reflect the amount of kidney function .(University of Maryland Medical Center . 2017) .

#### 2.2.5Creatine

Creatine is produced in liver, kidney, and pancreas and transported into skeletal muscles through the blood. Creatine can also be taken as a

supplement ,The non-enzymatic degradation of creatine in the skeletal muscles produces creatinine, which is excreted from the body as a waste.

Creatine is used in providing energy to the skeletal muscles during their high intensive functioning.

Creatinine is used in revealing kidney function. The main difference between creatine and creatinine is the function of each compound in the body ( University of Maryland Medical center,.2017) .

**Table(2. 1) shows the comparison between Creatinine and creatine**

	Creatine	Creatinine
Compound	2-carbamimidoyl- methyl-amine acetic acid .	2-amino – 1- methyl -5h-imidazol -4-one .
Molecular Formula	C <sub>4</sub> H <sub>9</sub> N <sub>3</sub> O <sub>2</sub>	C <sub>4</sub> H <sub>7</sub> N <sub>3</sub> O
Molecular Structure	Linear molecule	Heterocyclic structure
Significance	Used as supplement to increase the muscle mass	Waste product of creatine metabolism
Produce in	Liver , kidney and pancreas	Skeletal muscles
Role	Supply energy to muscles	Diagnosing the functioning of the kidney

#### 2.2.5.1Creatine disorders

There are two known disorders of creatine synthesis (both transmitted as autosomal recessive traits): arginine: glycine amidino transferase (AGAT)

deficiency; OMIM 602360; and guanidine acetate methyl transferase (GAMT) deficiency (OMIM601240)) and one disorder of creatine transport (X-linked recessive SLC6A8 Creatine transport deficiency (OMIM 300036)). (NicolaLango *et al* .,2011).

## 2.6 Chemotherapy

### 2.6.1 Definition Chemotherapy

Drugs kill or disable cancer cell in the breast or other places in the body . it helps lower the risk of the cancer returning (Susan G.,2020) .

### 2.6.2 Common Chemotherapeutic Agent

Platinum-derived drugs include cisplatin, carboplatin, oxaliplatin and nedaplatin , Nephrotoxicity represents the limiting factor of these drugs . Compared with cisplatin and nedaplatin, carboplatin and oxaliplatin appear to be less nephrotoxic and associated with less electrolyte derangements . Cisplatin nephrotoxicity results from cell damage in the S3 segment of the proximal tubule, distal convoluted tubules and collecting ducts .

Electrolyte disorders are also related to cisplatin-induced DNA damage of thiazide-sensitive sodium-chloride co-transporter genes and to the apoptosis of distal tubule cells . Cisplatin treatment may cause hyponatremia through SIADH, related to both higher secretion of and sensitivity to ADH .

Nausea and vomiting, which are common side effects of platinum-derived chemotherapy, are also powerful stimuli for ADH secretion. The incidence of hyponatremia can reach 59% (severe hyponatremia 12%) with cisplatin, whereas 20% is reported with carboplatin . Rarely, cisplatin-related hyponatremia may result from Renal Salt Wasting Syndrome .

Hypernatremia can also develop with cisplatin due to acquired nephrogenic diabetes insipidus with ensuing hypotonic polyuria .(Veronica Torres da Costa e Silva *et al* .,2018).

## **Chapter Three**

### **3. Material and methods**

#### **3.1 Materials:**

### **3.1.1 Study design**

This study was descriptive ,analytical ,hospital based cross sectional study.

### **3.1.2 Study area**

The study was conducted in **POROJ ALAMAL HOSPITAL** located in Khartoum state.

### **3.1.3 Study period**

The study was carried during period from September 2019 to April

### **3.1.4 Target population and sample size**

The study include(70) seventy patients under chemotherapy .

### **3.1.5 Inclusion criteria**

Cancer patients under chemotherapy .

### **3.1.6 Exclusion criteria**

Cancer patients not under chemotherapy

### **3.1.7 Ethical consideration**

The objectives of the study were explained to all individuals participating in the study ,and was approved by committee of clinical chemistry department, college of medical laboratory science, Sudan university of science and technology.

### **3.1.8 Data collection**

Data collected from hospital files.

### **3.1.8.1 Blood samples collection**

2.5ml of venous blood were collected in heparin containers, then plasma was separated in appendoorff tubes and store at  $-20$  until used.

## **3.2methods**

Serum potassium , sodium ,urea and creatine were measured using Mindray BS200 automated system.

### **3.2.1measurement of potassium**

#### **3.2.1.1principle of the method**

The amount of potassium is determined by using sodium tetraphenylboron in specifically prepared mixture to produce a colloidal suspension . the turbidity of which is proportional to concentration of K in range of 2\_7 mEq/ l .

#### **3.2.1.2procedure See appendix(1).**

### **3.2.2measurement of sodium**

#### **3.2.2.1principle of the method**

The Present method is based on reaction of sodium with a selective chromogen producing a chromophore whose absorbance varies directly at the concentration of sodium in test.



### **3.2.2.2 procedure See appendix(2)**

## **3.2.3 measurement of urea**

### **3.2.3.1 principle of the method**

#### **3.2.3.1.1 direct method**

urea in sample react. With orthphaladhyde in acidic media (boric acid) give pink colour read in 520nm.

#### **3.2.3.1.2 urea**

in sample react with (DAM) in acidic media (HSO) in high temperature and presence of activator (TSC), ferric chloride and codamine ions.

#### **3.2.3.2 indirect method**

(urea hydrolysis (berthelot reaction)) Urea in sample hydrolysis by urease enzyme to ammonia(NH) and CO<sub>2</sub>, ammonia.

In the presence of glutamate dehydrogenase (GLDH) and reduced nicotinamide adenine dinucleotide (NADH) .the ammonia combines with a.ketoglutarate (a.KG) to produce l-glutamate . the rate decrease in the NADH concentration is directly proportional to the urea concentration in the specimen . it determined by measuring the absorbance at 340 nm.

### **3.2.3.2 procedure See appendix(3)**

## **3.2.4 measurement of creatinine**

### **3.2.4.1 principle of the method**

Creatinine reacts with picric acid in alkaline conditions to form a yellow-orange color complex. The rate of formation of color is proportional to the creatinine quantity in the sample

#### **3.2.4.2 procedure See appendix(4)**

### **3.3 Quality Control**

The precision and accuracy of all methods used in this study were checked by commercially prepared control ( control serum normal 1 and control serum abnormal 2) sample before application for the measurement of test and control sample .

### **3.4 Statistical Analysis**

Data analysis was done using statistical package of social science (SSPS version 19), the mean and standard deviations of potassium ,sodium ,urea and creatinine were calculated and one sample T test and correlation was used for comparison.

## **Chapter four**

### **Result**

Electrolyte derangement has been documented during cancer chemotherapy leading to the electrolyte imbalance. and disturbance of renal function. A total of 70 cancer patients were selected. The age range of the included patient was 10 \_ 77 years who received single or combination chemotherapy.

The mean age of patients age was 38. In our study significant difference existed in electrolytes parameters. In our study potassium level after the chemotherapy was 3.43 mg/dl ( $p < 0.001$ ) while sodium level after the chemotherapy was 131.77mg/dl ( $p < 0.001$ ) . urea level after chemotherapy was 35.30mg/dl ( $p < 0.001$ ) . while recorded creatinine levels after chemotherapy was 0.82 mg/dl ( $p < 0.001$ ). Sodium, potassium, creatinine and urea levels show insignificant p value.

There was insignificant weak positive correlation between urea levels (mg/dl) and age (year) person correlation ( $r = 0.203$ ) and p . value (0.09) . There was insignificant weak positive correlation between creatinine levels (mg/dl) and age (year) person correlation ( $r = 0.177$ ) and p . value (0.14) .

There was insignificant weak negative correlation between sodium levels (mg/dl) and age (year) person correlation ( $r = - 0.143$ ) and p . value (0.23) .

There was insignificant weak negative correlation between potassium levels (mg/dl) and age (year) person correlation ( $r = -0.219$ ) and p . value (0.06)

**Table (4.2). the mean and Std. deviation of Urea, Creatinine, Sodium and Potassium.**

	Age	Blood urea	creatinine	Sodium	Potassium
NO. sample	70	70	70	70	70
Mean	38	35.30	0.82	131.77	3.43
Std .D	16.85	26.07	0.44	3.1	0.63




Figure (4.1) represented insignificant correlation between urea levels (mg/dl) and age (year) ( $r=0.23$ ) ( $p=0.09$ ) .




Figure (4.2) represented insignificant correlation between creatinine levels (mg/dl) and age (year) ( $r= 0.177$ ) ( $p=0.14$ ) .




Figure (4.3) represented significant// 49

9represented insignificant correlation between sodium levels (mg/dl) and age (year) ( $r=-0.143$ ) ( $p=0.23$ ) .




Figure (4.4) represented significant correlation between potassium levels (mg/dl) and age (year)( $r=-0.219$ ) ( $p=0.06$ ) .



## Chapter five

### 5. Discussion, Conclusion and Recommendation

#### 5.1 Discussion

Chemotherapy drugs kill or disable cancer cell, it help lower the risk of cancer. Our results are in accordance with earlier studies which showed the levels of electrolytes are changed after chemotherapy

In the study under discussion there is a drop of sodium level below normal level and the mean recorded sodium level is 131.77mg/dl with insignificant p value(0.00) . In our study almost all the patients had normal potassium, urea and creatinine levels after the start of chemotherapy regime. The overall findings in the studies mentioned above. Similar observation has been recorded in (kumari *et al.* 2015), (lauray-Vacher *et al.* 2016).

In the present study in case of chemotherapy effect on renal function and electrolyte the level of sodium, potassium level show in significant p. value (<0.001) similar finding has been recorded in (kumari *et al.* 2015), (lauray-Vacher *et al.* 2016).

In this study significant negative correlation between serum sodium and age of the patient (R=-0.143), p .value (0.23), significant negative correlation between serum potassium and age of the patient (R=-0.219), p. value (0.06), significant positive correlation between serum urea and age of the patient (R=0.203), p. value (0.09), significant positive correlation between serum creatinine and age of the patient (R=0.177), p .value (0.14).

## 5.2 conclusion

The study has concluded that there are variations in electrolytes parameters in patients receiving chemotherapy. Our study showed that patients during

chemotherapy develop electrolyte imbalances mainly in sodium and potassium.

### 5.3. Recommendation

Other study recommended to investigate the renal profile &electrolyte in patients under chemotherapy , including large number of participant , conducted as prospective study , include other electrolyte ( phosphate , calcium , magnesium and other trace elements ) and include other variable as BMI ,treatment type (single /combination drug) and diet habits .Based on these observations recommended to all patients under chemotherapy electrolyte should be investigated. and focus on electrolyte imbalance , so that the appropriate chemotherapeutic plan can be devised to manage the

patients accordingly. This may help to decrease mortality and morbidity in future.

## References

**Allolio B, Annane D, Ball S, et al.**(2014), Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Intensive Care Med.*; 40: 320-331.

**Anderson .R.G** (1986). Hospital acquired hyponatraemia. *Kidney In* 29:1237-35.

**ANTHONY J. VIERA, MD, MPH, et al.** (2010), University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina(2. Lippi G, Favaloro EJ, Montagnana M, Guidi GC. Prevalence of Hypokalemia: the experience of a large academic hospital. *Intern Med J.* 40(4):315-316.

**ANTHONYJ.VIERA, MD, MPH, et al.** (2015),University of North Carolina at Chaple Hill , North Carolina volume (92);number.(Shemer J, Modan M, Ezra D, Cabili S. Incidence of Hyperkalemia in patients. *Isr J Med Sci.* 1938;19 (7):659- 661. And

**Bellows .L, Moore .R.**(2013).Potassium and the diet, *Food and Nutrition series*. Fact sheet No9.335

**Bishop M L . Fody E P. Schoeff L E .** (2010). Clinical chemistry techniques , principles , correlation , 6 th , Lippincott Williams and wikins , London: p 373-377.

**Bowman BT,**(2017). Electrolyte Disorders Associated with Cancer. *J. Onco-Nephrology.*; 1(1): 30-35.

**Carvalho F, Louro F, Zakout R.**(2015). Adrenal Insufficiency in Metastatic Lung Cancer. *World Journal of Oncology.* 6(3): 375-377.

**Colorado State University (2013)** , U.S. Department of Agriculture and Colorado counties cooperating.

**D. C.** (2005)Mikulecky Faculty Mentoring Program Virginia Commonwealth Univ. Evans KJ , Greenberg A. Hyprekalemia : a review . *J Intensive Care Med*;20 (5):272-290.

**G Giebisch, R Krapf , C Wagner**(2007) : Higgins C.Urea and the clinical value measuring blood urea concentration. *kidney international* 72, 397-410.

**Ganong WF**(2015). Review of medical physiology, 18<sup>th</sup> edn. Connecticut. Moritz ML, Ayus JC. Maintenance intravenous fluids in acutely ill patients. *New England Journal of Medicine.* 373(14):1350- 1360. DOI: 10.1056/NEJMra1412877 .

**Kitai Y, Matsubara T, Yanagita M(2015).** Onco-nephrology: current concepts and future perspectives. *Japanese journal of clinical oncology*.; 45(7): 617-628.

**Kumar RV, Bhasker S(2015).** Health-care related supportive-care factors may be responsible for poorer survival of cancer patients in developing countries. *Journal of Cancer Policy*. 5: 31-47.

**Lameire N(2014).** Nephrotoxicity of recent anti-cancer agents. *Clinical kidney journal*. 7(1):11-22..

**Lameire N(2014).** Nephrotoxicity of recent anti-cancer agents. *Clinical kidney journal*. 7(1):11-22.

**Lameire N, Van Biesen W, Vanholder R(2010).** Electrolyte disturbances and acute kidney injury in patients with cancer. *In Seminars in nephrology*. 30(6): 534-547.

**Liamis G, Rodenburg EM, Hofman A, et al(2013).** Electrolyte disorders in community subjects: prevalence and risk factors. *Am J Med*.;126(3):256-263.).

**Moritz ML, Ayus JC.(2015).** Maintenance intravenous fluids in acutely ill patients. *New England Journal of Medicine*. 373(14):1350-1360.

**Lameire N, Van Biesen W, Vanholder R.(2010).** Electrolyte disturbances and acute kidney injury in patients with cancer. *In Seminars in nephrology*. 30(6): 534-547.

**Carvalho F, Louro F, Zakout R.(2015).** Adrenal Insufficiency in Metastatic

Lung Cancer. *World Journal of Oncology*. 6(3): 375-377.

**Kitai Y, Matsubara T, Yanagita M.**(2015). Onco-nephrology: current concepts and future perspectives. *Japanese journal of clinical oncology*. 45(7): 617-628.

**Nicola Longo**(2011) , Genet C and C Semin Disorders of creatine transport and metabolism. *A M J Med* ,

**Nriagu J, Darroudi F, Shomar B.** (2016). Health effects of desalinated water: Role of electrolyte disturbance in cancer development. *Enviro Res*.150:191-204.

**Kumar RV, Bhasker S**(2015) . Health-care related supportive-care factors may be responsible for poorer survival of cancer patients in developing countries. *J. Cancer Policy*. 5: 31-47.

**Nriagu J, Darroudi F, Shomar B.** (2016). Health effects of desalinated water: Role of electrolyte disturbance in cancer development. *Environmental Research*. 150:191-204. Prentice Hall international Inc. 1997.

**Paice B ,Gray J M , McBride D ,et al**(1983).Hyperkalemia in patients in hospital. *Br Med J ( Clin Res Ed)*. 339(7): 451-458.

**Susan G.Komen** 1-877-465-6636 komen.org.

**University of Maryland Medical Center**(2017).”creatine “ .N.P. n . p. Web.

## BioMed-Sodium

### Colorimetric, Endpoint

REF: SOD100100 (2 x 50 ml)  
SOD100040 (2 x 20 ml)



#### INTENDED FOR USE:

For the quantitative determination of Sodium in serum.

#### PRINCIPLE:

The Present method is based on reaction of sodium with a selective chromogen producing a chromophore whose absorbance varies directly at the concentration of sodium in test.

#### SPECIMEN COLLECTION:

Freshly drawn non hemolysed serum is the specimen of choice.

Serum Sodium is stable for atleast 24 hours at room temperature and two weeks at 2-8°C. Serum or heparinised plasma, CSF & Urine. Urine diluted 1+1 with distilled water can be used for chloride estimation. Chloride in serum is stable for 7 days at 2-8°C.

#### REAGENT COMPOSITIONS :

R1 Standard	Sodium	150 mEq/l
R2 Color Reagent	Color reagent	

#### PACKAGE: Collection and storage.

Store all reagents at +2-8°C the reagents are stable until the expiration date as indicated on the label.

#### PRECAUTIONS & WARNING :

Avoid pipette with mouth.

The preparation, according to current regulation, is classified as not dangerous.

The total concentration of non active components (preservatives, detergents, stabilizers) is below the minimum required for citation.

Anyway handle with care, avoid ingestion, avoid contact with eyes, skin and mucous membranes. The samples must be handle as potentially infected from HIV or Hepatitis.

#### REAGENT PREPARATION & STABILITY :

Liquid reagents must be at room temperature (+15-25°C) before using.

#### REQUIRED MATERIALS NOT PROVIDED:

General Laboratory Equipment and instrumentations.

#### PROCEDURE:

Wavelength: 623nm (620-640)  
Optical path: 1 cm light path  
Temperature: +25/30/37°C.  
Reading: Against reagent blank  
Assay type: End Point

#### Pipetting in tubes:

	BLANK	STANDARD	SAMPLE
Reagent (R2)	1ml	1ml	1ml
Distilled water	10 µL		
Standard		10 µL	
Sample			10 µL

Mix, incubate for 5 min at room temperature (+15-25°C.) Read the absorbance of standard and sample tubes.

Volumes can be proportionally modified.

This methodology describes the manual procedure to use the kit.

For automated procedure, ask for specific application.

#### CALCULATION:

$$\text{Sodium mEq/l} = \frac{(A) \text{ Sample}}{(A) \text{ Standard}} \times 150$$

#### EXPECTED VALUE:

Serum: 135 - 155 mEq/l

The above mentioned values are to be considered as a reference. It is strongly recommended that each laboratory establish its own normal range according to its geographic area, according to IFCC protocol.

#### WASTE DISPOSAL:

The disposal of the product must be in accordance with local regulation concerning waste disposal.

#### QUALITY CONTROL:

It is recommended to execute the quality control at every kit utilization to verify that values are with in the reference range indicated by the methodology.

#### INTERFERENCE:

Turbid or icteric serum produce falsely elevated results.

#### Linearity :

The assay is linear up to Sodium 200 mEq/l

#### REFERENCES:

- 1- Tietz, N.W., Fundamentals of Clinical Chemistry, W.B.Saunders Co., Phila, P.A.p.874.
- 2- Henry R.F., et, al, Clinical Chemistry Principles and Technics. 2nd Ed, Harper and Row, Harper and 3- Row, Hargresein, M.D.(1974).
- 4- Maruna RFL., Clin Chem. Acta. 2:581, (1958).
- 5- Trinder, P:Analyst, 76:596, (1951).

	Consult Instructions for Use
	Caution, Consult accompanying Documents
	In Vitro Diagnostic Medical Device
	Temperature Limitation
	Manufacturer
	Authorized Representative in the European Community
	Catalogue Number
	Batch Code
	Use by

<b>EGY-CHEM</b> for lab technology Badr City, Industrial Area Piece 170 250 Fadan in East of Elrubaki, EGYPT Office Tel: +202 26236727 / +202 26236598 Factory Tel: +202 23108170 / +202 23108171 Fax: +202 26240986 www.egychem.com	 <b>MDSS GmbH</b> Schiffgraben 41 30175 Hannover, Germany



## List of abbreviation

A urea cycle disorder	AUCD
Arginine glycine amido transferase	AGAT
Bicarbonate	Na <sub>2</sub> CO <sub>3</sub>
Calcium	Ca <sup>2+</sup>
Chloride	Cl <sup>-</sup>
Guanidine aceto methyl transferase	GAMT
Magnesium	Mg <sup>2+</sup>
Potassium	K <sup>+</sup>
Sodium	Na <sup>+</sup>
Sulphate	SO <sub>4</sub> <sup>2-</sup>
Total body water	TBW